Fingolimod is a disease modifying therapy (DMT) in highly active relapsing remitting multiple sclerosis (RRMS), as is natalizumab
This case describes a 31-year old woman with RRMS, who experienced severe side effects on natalizumab. After a voluntary four months treatment free period, a severe relapse appeared which was treated with prednisone and plasmapheresis; thereafter fingolimod was initiated. In the following months MRI signs improved spectacularly.
This case suggests that fingolimod might be a good alternative for natalizumab, especially for use in RRMS patients, with highly active, advanced disease, when natalizumab treatment is stopped due to side effects or even after a severe relapse.
Fingolimod (FTY720, Gilenya®, Novartis Pharma AG, Basel, Switzerland)
Although this study references only one case, the results do bear more research, particularly as those who are longer adherents to the natalizumab (Tysabri) DMT begin to consider alternatives to help mitigate the potential risks of developing PML.